A Critical Review of Substitution Policies for Biosimilars in Canada (GaBI Journal, 2021)
US Biosimilar Market on Pace with Europe (GaBI Journal, 2020)
European prescribers’ attitudes and beliefs on biologicals prescribing and automatic substitution (GaBI Journal, 2020)
Policy recommendations for a sustainable biosimilars market: lessons from Europe (GaBI Journal, 2020)
Medicines regulation in the MENA Region and the importance of the World Health Organization’s INN proposal of Biological Qualifier (GaBI Journal, 2018)
A survey of Australian prescribers’ views on the naming and substitution of biologicals (GaBI Journal, 2017)
Naming and labelling of biologicals – a survey of US physicians’ perspectives (GaBI Journal, 2017)
Clear naming, traceability of biological medicines will protect patients (GaBI Journal, 2017)
Naming and labelling of biologicals – the perspective of hospital and retail pharmacists (GaBI Journal, 2015)
Prescribing practices for biosimilars: questionnaire survey findings from physicians in Argentina, Brazil, Colombia and Mexico (GaBI Journal, 2015)
Biosimilars naming, label transparency and authority of choice – survey findings among European physicians (GaBI Journal, 2014)
The future of biological therapy: a pathway forward for biosimilars (GaBI Journal, 2013)
‘It’s all about the name: what is the imperative of adopting unique names for biologic and biosimilar therapeutics?’ (Food and Drug Law Institute, 2012)
